

SEATTLE REPERTORY THEATER
Consolidated Financial Statements
For the Year Ended June 30, 2025

Table of Contents

	Page
Independent Auditor's Report	1 - 3
Financial Statements:	
Consolidated Balance Sheet	4
Consolidated Statement of Activities	5 - 6
Consolidated Statement of Functional Expenses	7
Consolidated Statement of Cash Flows	8
Notes to Consolidated Financial Statements	9 - 22
Supplementary Information:	
Consolidating Schedule - Balance Sheet	23
Consolidating Schedule - Statement of Activities	24
Consolidating Schedule - Statement of Cash Flows	25

Independent Auditor's Report

**To the Boards of Trustees
Seattle Repertory Theater
Seattle, Washington**

Opinion

We have audited the financial statements of Seattle Repertory Theater and Seattle Repertory Theater Foundation (collectively, the Organization), which comprise the consolidated balance sheet as of June 30, 2025, and the related consolidated statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Organization as of June 30, 2025, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Report on Summarized Comparative Information

We have previously audited the Organization's June 30, 2024 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated November 12, 2024. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2024 is consistent, in all material respects, with the audited financial statements from which it has been derived.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.



T: 425-454-4919
T: 800-504-8747
F: 425-454-4620

555 110th Ave NE
Suite 700
Bellevue, WA
98004

clarknuber.com

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The consolidating schedules on pages 23 through 25 are presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

Clark Nuber PS

Certified Public Accountants
November 20, 2025

SEATTLE REPERTORY THEATER

Consolidated Balance Sheet

June 30, 2025

(With Comparative Totals for 2024)

	2025	2024
Assets		
Current Assets:		
Cash	\$ 131,768	\$ 35,392
Cash reserves (Note 1)	1,997,619	1,413,060
Restricted cash (Note 1 and 8)	21,347	16,838
Accounts receivable, net	101,984	107,004
Pledges receivable, net (Note 2)	1,139,969	2,644,880
Prepaid expenses and inventory	461,708	412,785
Total Current Assets	3,854,395	4,629,959
Cash restricted for endowment		624,144
Investments, long-term (Note 3)	15,090,842	13,546,226
Pledges receivable for capital purposes (Note 2)	50,000	177,488
Pledges receivable, long-term, net (Note 2)	655,177	229,663
Property and equipment, net of accumulated depreciation (Note 4)	6,563,169	6,179,795
Financing lease, right-of-use asset (Note 8)		97,460
Total Assets	\$ 26,213,583	\$ 25,484,735
Liabilities and Net Assets		
Current Liabilities:		
Deferred ticket revenue	\$ 1,816,543	\$ 1,698,724
Accounts payable and accrued liabilities	1,110,221	959,584
Line of credit (Note 11)	1,145,000	65,000
Current portion of financing lease liability (Note 8)		29,081
Total Liabilities	4,071,764	2,752,389
Net Assets:		
Without donor restrictions (Note 5)	6,546,275	3,966,705
With donor restrictions (Note 6)	15,595,544	18,765,641
Total Net Assets	22,141,819	22,732,346
Total Liabilities and Net Assets	\$ 26,213,583	\$ 25,484,735

See accompanying notes.

SEATTLE REPERTORY THEATER

Consolidated Statement of Activities For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

	Without Donor Restrictions	With Donor Restrictions	2025 Total	2024 Total
Operating Revenue				
Box Office Income:				
Subscription revenue	\$ 2,055,721	\$ -	\$ 2,055,721	\$ 1,884,318
Single ticket revenue	2,191,219		2,191,219	1,984,283
Service fees	421,623		421,623	391,624
Total Box Office Income	4,668,563		4,668,563	4,260,225
Other Earned Income:				
Royalty income	161,894		161,894	74,440
Production fees	80,681		80,681	123,034
Other revenue, net of related expenses	302,970		302,970	157,936
Total Other Earned Income	545,545		545,545	355,410
Total Box Office and Earned Income	5,214,108		5,214,108	4,615,635
Contributions:				
Individual gifts	4,638,296	513,417	5,151,713	3,714,599
Corporate	108,500	60,000	168,500	259,500
Foundations	1,314,211	10,000	1,324,211	612,935
Advocacy	107,937		107,937	109,040
Government	500,730	36,000	536,730	44,930
In-kind gifts	42,738		42,738	28,928
Fundraising events, net of related expenses	852,630		852,630	1,183,582
Other pandemic relief revenue				89,392
Contributions released from restrictions (Act I campaign, Note 2)	2,335,102		2,335,102	3,413,444
Endowment appropriation (Note 7)	776,447		776,447	777,023
Contributions released from restrictions	389,633	(389,633)		
Total Contributions	11,066,224	229,784	11,296,008	10,233,373
Total Operating Revenue	16,280,332	229,784	16,510,116	14,849,008

See accompanying notes.

SEATTLE REPERTORY THEATER

Consolidated Statement of Activities (Continued) For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

	Without Donor Restrictions	With Donor Restrictions	2025 Total	2024 Total
Operating Expenses:				
Artistic	2,325,325		2,325,325	2,500,241
Production	6,438,828		6,438,828	5,537,811
Marketing and communications	3,368,890		3,368,890	3,429,742
Development	1,146,895		1,146,895	1,317,996
Administration	1,923,328		1,923,328	2,167,744
Total Operating Expenses	15,203,266		15,203,266	14,953,534
Change in Net Assets Before Depreciation and Nonoperating Activity	1,077,066	229,784	1,306,850	(104,526)
Depreciation and amortization	799,489		799,489	795,581
Nonoperating Activity:				
Contributions to the Act I campaign (Note 2)		335,101	335,101	4,073,025
Contributions released from restrictions (Act 1 campaign, Note 2)	2,194,963	(4,530,065)	(2,335,102)	(3,413,444)
Release of Foundation net assets	883,477	(883,477)		
Endowment investment return		1,543,579	1,543,579	1,776,375
Contributions to endowment		134,981	134,981	624,144
Endowment appropriation (Note 7)	(776,447)		(776,447)	(777,023)
Total Nonoperating Activity	2,301,993	(3,399,881)	(1,097,888)	2,283,077
Total Change in Net Assets	2,579,570	(3,170,097)	(590,527)	1,382,970
Net Assets:				
Beginning of year	3,966,705	18,765,641	22,732,346	21,349,376
End of Year	\$ 6,546,275	\$15,595,544	\$22,141,819	\$22,732,346

See accompanying notes.

SEATTLE REPERTORY THEATER

Consolidated Statement of Functional Expenses For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

	Artistic	Production	Marketing and Communications	Total Program	Development	Administration	2025 Total	2024 Total
Payroll costs-								
Salaries	\$ 601,689	\$ 4,194,354	\$ 1,652,816	\$ 6,448,859	\$ 844,199	\$ 1,190,607	\$ 8,483,665	\$ 8,149,608
Benefits and taxes	95,779	1,093,056	332,976	1,521,811	180,669	196,779	1,899,259	1,981,287
Total payroll costs	697,468	5,287,410	1,985,792	7,970,670	1,024,868	1,387,386	10,382,924	10,130,895
Other expenses-								
Royalties	530,430			530,430			530,430	196,905
Co-production fees	453,085			453,085			453,085	710,088
Production materials		413,491		413,491	454		413,945	218,785
Artist housing	65,760	38,455		104,215			104,215	99,042
Travel, housing, and meetings	205,018	112,413	11,266	328,697	65,940	19,641	414,278	475,368
Advertising			599,172	599,172	440	3,849	603,461	682,367
Printing and publications	4,702		159,952	164,654	16,142	1,078	181,874	178,723
Professional fees	366,471	37,464	249,300	653,235	21,956	271,952	947,143	937,187
Supplies and equipment	2,270	59,584	88,355	150,209	1,096	59,802	211,107	224,745
Postage and shipping	121	4,796	5,004	9,921	4,323	7,851	22,095	44,161
Facilities		479,608	139,811	619,419		118,749	738,168	743,067
Bank service charges, taxes, and miscellaneous		5,607	130,238	135,845	11,676	53,020	200,541	312,201
Total other expenses	1,627,857	1,151,418	1,383,098	4,162,373	122,027	535,942	4,820,342	4,822,639
Total Expenses Presented on the Consolidated Statement of Activities	2,325,325	6,438,828	3,368,890	12,133,043	1,146,895	1,923,328	15,203,266	14,953,534
Plus expenses netted with revenues and depreciation and amortization-								
Bar and concessions			278,002	278,002			278,002	197,182
Theater rental	110,030			110,030			110,030	33,570
Special event direct donor costs					323,204		323,204	345,000
Depreciation and amortization		661,439	44,228	705,667		93,822	799,489	795,581
Total Functional Expenses	\$ 2,435,355	\$ 7,100,267	\$ 3,691,120	\$ 13,226,742	\$ 1,470,099	\$ 2,017,150	\$ 16,713,991	\$ 16,324,867
Total 2024 Functional Expenses	\$ 2,533,811	\$ 6,203,233	\$ 3,668,522	\$ 12,405,566	\$ 1,662,996	\$ 2,256,305		\$ 16,324,867

See accompanying notes.

SEATTLE REPERTORY THEATER

Consolidated Statement of Cash Flows For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

	2025	2024
Operating Activities:		
Change in net assets	\$ (590,527)	\$ 1,382,970
Adjustments to reconcile change in net assets to net cash used in operating activities-		
Depreciation and amortization	799,489	795,581
Net gain on investments	(1,298,701)	(1,532,407)
Contributions and investment return restricted for endowment	(194,495)	(722,077)
Contributions restricted for capital purposes	(126,377)	(564,000)
Cash (used) provided by changes in operating assets and liabilities:		
Accounts receivable	5,020	(3,374)
Pledges receivable	1,206,885	314,309
Pledges receivable for capital purposes	(127,488)	177,488
Prepaid expenses and inventory	(48,923)	(76,690)
Deferred ticket revenue	117,819	58,933
Accounts payable and accrued liabilities	242,539	(111,996)
Net Cash Used in Operating Activities	(14,759)	(281,263)
Investing Activities:		
Purchase of investments	(2,731,530)	(3,927,116)
Proceeds from sale of investments	2,485,615	4,514,017
Purchase of property and equipment	(1,177,305)	(211,427)
Net Cash (Used in) Provided by Investing Activities	(1,423,220)	375,474
Financing Activities:		
Collections on contributions and investment return restricted for endowment corpus	194,495	722,077
Collections on contributions for capital purposes	253,865	386,512
Payments on line of credit	(5,952,000)	(14,124,000)
Proceeds from line of credit	7,032,000	12,098,468
Payments of financing lease liabilities	(29,081)	(112,176)
Net Cash Provided by (Used in) Financing Activities	1,499,279	(1,029,119)
Net Change in Cash, Cash Reserves, and Restricted Cash	61,300	(934,908)
Cash, cash reserves, and restricted cash, beginning of year	2,089,434	3,024,342
Cash, Cash Reserves, and Restricted Cash, End of Year	\$ 2,150,734	\$ 2,089,434
Reconciliation to Consolidated Balance Sheet:		
Cash	\$ 131,768	\$ 35,392
Cash reserves	1,997,619	1,413,060
Restricted cash	21,347	16,838
Cash restricted for endowment		624,144
Cash, Cash Reserves and Restricted Cash	\$ 2,150,734	\$ 2,089,434
Supplementary Disclosure:		
Cash paid for interest	\$ 15,058	\$ 115,595
Property and equipment in accounts payable	\$ -	\$ 91,905
Acquisition of long-term assets at the conclusion of financing leases	\$ 87,364	\$ 193,852

See accompanying notes.

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

Note 1 - Summary of Significant Accounting Policies

General - Seattle Repertory Theater's (the Theater) mission is to collaborate with extraordinary artists to create productions and programs that reflect and elevate the diverse cultures, perspectives, and life experiences of our region. Our vision for the Theater is to put theater at the heart of public life, positioning the work on our stages as a vital source for collective imagination, unbounded creativity, and meaningful conversation and social debate. The Theater was founded in 1963 by local citizens as a civic investment in a thriving community and has been awarded the Tony Award for Outstanding Regional Theater in recognition for its consistently high production and artistic standards. Over the last 59 years, the Theater has become both a home for local artists and a national incubator and destination for great art. Under the leadership of Artistic Director Braden Abraham through January 22, 2023, Artistic Director Dámaso Rodríguez starting July 31, 2023, and Managing Director Jeffrey Herrmann, the Theater serves approximately 120,000 audience members and program participants each year through our mainstage subscription season, new play readings and workshops, youth arts education programs, and community engagement initiatives.

The Seattle Repertory Theater Foundation (the Foundation) was founded in 1998 to conduct and support activities exclusively for the benefit of the Theater. The Foundation receives and holds endowment funds for, and makes distributions to, the Theater. The endowed funds are also used to collateralize the line of credit and other banking functions of the Theater's operations.

Principles of Consolidation - The accounts of the Theater and the Foundation (collectively, the Organization), have been consolidated in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) which require that financially interrelated organizations be consolidated. All intercompany transactions and balances have been eliminated.

Basis of Presentation - The financial statements of the Organization have been prepared on the accrual basis of accounting. The Organization reports information regarding its financial position and activities according to two classes of net assets: net assets without donor restriction and net assets with donor restriction.

Net Assets Without Donor Restriction - Net assets that are not subject to or are no longer subject to donor-imposed stipulations.

Net Assets With Donor Restriction - Net assets that are subject to donor restrictions consist of both donor-imposed stipulations that will be met either by actions of the Organization and/or the passage of time and those subject to donor-imposed stipulations specifying that the Organization maintain the assets in perpetuity.

Revenues are reported as increases in net assets without donor restriction unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restriction. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions unless their use is restricted by explicit donor stipulation or by law. Expirations of donor restrictions on the net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as reclassifications between the applicable classes of net assets. The Organization has adopted a policy to classify donor restricted contributions as without donor restrictions to the extent that donor restrictions were met in the year the contribution was received.

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

Note 1 - Continued

Use of Estimates - The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Income Tax Status - The Theater and the Foundation have been notified by the Internal Revenue Service that they are both exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code. The Foundation and the Theater are further classified as organizations that are not private foundations under Section 509(a)(3) of the Code. Accordingly, no provision for income taxes has been recorded.

Cash - For purposes of the consolidated statement of cash flow, cash includes cash on hand and in banks except for cash equivalents associated with the investment accounts.

Cash Reserves - Cash reserves represent operating and capital reserves (Note 5).

Restricted Cash - Restricted cash represents cash associated with gift annuities.

Revenue Recognition -

Subscriptions, Single Tickets, and Service Fees - The Organization presents theater performances and earns revenue from ticket sales. Tickets are sold in subscription packages and as single tickets and are generally purchased by customers in advance of the performances. Service fees are processed as a portion of ticket sales. Tickets sold are nonrefundable. The Organization's performance obligation for each ticket is to provide a seat at the applicable performance. Revenue from subscription packages and single tickets are recognized at the time the performance occurs.

Production Fees - The Organization partners with commercial producers and other theaters to produce performances. The Organization receives fees from these partners to offset the costs of such productions. The fees are agreed to in advance with co-producers, including which costs are to be shared, and the timing of payments. Revenue from production fees is recorded when received.

Contribution Revenue - The Organization recognizes contributions when cash, securities, or other assets; an unconditional promise to give; or a notification of a beneficial interest is received. Conditional promises to give are not recognized as revenues until the conditions on which they depend have been met. Contribution amounts received that are designated for future periods or restricted by the donor for specific purposes are reported as net assets with donor restrictions. At June 30, 2025, outstanding conditional contributions of \$142,500 were pledged for capital projects. At June 30, 2024, outstanding conditional contributions were \$325,000. All outstanding conditional contributions at June 30, 2024 were recognized in the year ended June 30, 2025.

The Organization uses the allowance method to determine uncollectible unconditional pledges receivable. The allowance is based on prior years' experience and management's analysis of specific promises made. There was an \$80,000 and \$30,000 allowance for uncollectible pledges as of June 30, 2025 and 2024, respectively. Contributions to be received after one year are discounted at an appropriate discount rate commensurate with the risk involved. Amortization of the discount is reported as contribution revenue.

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

Note 1 - Continued

In-Kind Gifts - The Organization recognizes contribution revenue for certain donated services and materials received at the market value at the time of contribution of those services and materials. During the years ending June 30, 2025 and 2024, contributed services and materials totaled \$127,507 and \$115,425, of which \$84,769 and \$86,497 were included in fundraising events revenue. In-kind contributions were used primarily in program and fundraising activities.

Functional Allocation of Expenses - Expenses consist of costs related to providing artistic, production, marketing, development, and administrative functions. These costs have been summarized on a functional basis in the consolidated statement of functional expenses. Costs are directly charged to the functions they benefit. Costs incurred in connection with specific performances are deferred until the show is performed. Facility related expenses are allocated to each function based on square footage utilized by the function.

Deferred Expenses - Production costs incurred associated with future shows are deferred and recognized and expensed as each show is performed.

Advertising Costs - The Organization expenses advertising costs as they are incurred. Total advertising expense for the year ended June 30, 2025 and 2024 was \$603,461 and \$682,367, respectively.

Receivables - Accounts and pledges receivable are stated at the amount the Organization expects to collect. The Organization has determined an allowance for credit losses based upon applying a credit loss rate to the account balance. The method applies an overall credit loss rate to the accounts or pledges receivable balance based upon historical loss rates adjusted for reasonable and supported forecasts. Balances that remain outstanding after the Organization has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts or pledges receivable.

Investments - Investments in debt securities and equity securities with readily determinable market values are recorded at fair value. Unrealized and realized gains and losses on these investments are reported in the consolidated statement of activities. Securities are generally held in custodial investment accounts administered by certain financial institutions (Note 3).

Nonoperating Activity - The Organization presents the activity associated with its endowment funds and capital campaign as a separate subsection within the consolidated statement of activities. The investment return and contributions and related releases of net asset restrictions to endowments and capital campaign are included in this subsection. The annual appropriation from the endowment to support the Theater's operations is presented as a transfer out of the endowment activity and a transfer into the contributions subsection of the consolidated statement of activities. Further information regarding the endowment funds and capital campaign is included in Note 7 and 2, respectively.

Property and Equipment - Equipment and leasehold improvements are stated at cost if purchased or fair market value if contributed. The Organization capitalized all assets greater than \$3,000 and an estimated useful life of more than one year.

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements
For the Year Ended June 30, 2025
(With Comparative Totals for 2024)

Note 1 - Continued

Depreciation and amortization are provided using the straight-line method over the estimated useful lives as follows:

Computer equipment	3 years
Other equipment	5 - 10 years
Building and improvements	30 years
Leasehold improvements	Shorter of asset life or life of lease

Leasehold improvements made near the end of the lease life where the Organization has the ability and intent to extend the lease are estimated to have a useful life consistent with similar assets where the underlying property is owned.

Gift Annuities - The Organization administers gift annuities for which it is obligated to make periodic distributions to designated beneficiaries. The contributed assets are recorded at their fair value as general assets of the Organization. The present value of the payments due to the beneficiaries are recorded as liabilities and totaled \$12,960 and \$13,525 at June 30, 2025 and 2024, respectively. Net present values are calculated using the applicable risk-free discount rate at the date of the gift. The annuity liability is revalued annually based upon actuarially computed present values. Resulting actuarial gain or loss is recorded as donor restricted revenue.

Concentration of Credit Risk - Financial instruments that potentially subject the Organization to concentration of credit risk consist primarily of receivables, cash, and investments. The concentration of credit risk with respect to receivables is limited due to a large base of donors consisting of public and private companies representing a variety of industries, government agencies, and individuals in the Pacific Northwest. The Organization does not require collateral or other security to support receivables. The Organization holds substantially all of its cash with one financial institution, and substantially all of its investments with another financial institution. These balances may at times exceed FDIC and SIPC insurance limits.

The Organization invests only with financial institutions with strong credit ratings and has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Organization monitors the performance of the financial institutions used to hold cash and investment balances to minimize the risk of balances held over FDIC and SIPC insurance limits.

Pledges receivable from two sources comprised 41% of total pledges receivable at June 30, 2025. Pledges receivable from two sources comprised 27% of total pledges receivable at June 30, 2024.

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

Note 1 - Continued

Leases - The Organization determines if an arrangement contains a lease at inception. Financing leases are included in right-of-use (ROU) assets and lease liabilities in the balance sheet. ROU assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent the Organization's obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Organization's leases do not provide an implicit rate of return; thus, the Organization uses the risk-free discount rate, determined using a period comparable with that of the lease term from the later of the lease commencement date or implementation date. The ROU asset also includes prepaid lease payments and/or unamortized initial direct costs and excludes any lease incentives. To the extent the Organization has lease agreements with lease and non-lease components, the Organization has elected to account for these as a single lease component. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Organization will exercise

that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. A ROU asset and operating lease liability is not recognized for leases with an initial term of 12 months or less.

Reclassifications - Certain items from the prior-year financial statements have been reclassified to conform to the current year presentation. These reclassifications had no impact on net assets or changes in net assets previously reported.

Comparative Amounts for 2024 - The financial statements include certain summarized comparative information in total, but not by net asset class, for the year ended June 30, 2024. Such information does not include sufficient detail to constitute a presentation in conformity with U.S. GAAP. Accordingly, such information should be read in conjunction with the Organization's financial statements for the year ended June 30, 2024, from which summarized information was derived.

Subsequent Events - The Organization has evaluated subsequent events through November 20, 2025, the date on which the financial statements were available to be issued.

Note 2 - Pledges Receivable

Pledges receivable at June 30 were as follows:

	Operating	Capital	Act I Campaign	AIF Campaign	2025	2024
Due in less than one year	\$ 625,098	\$ 50,000	\$ 189,371	\$ 325,500	\$ 1,189,969	\$ 2,822,368
Due in one to five years	52,500		78,000	650,000	780,500	286,090
	677,598	50,000	267,371	975,500	1,970,469	3,108,458
Present value discount (3.68% - 2025; 4.52% - 2024)	(21,403)			(23,920)	(45,323)	(26,427)
Allowance for doubtful accounts			(30,000)	(50,000)	(80,000)	(30,000)
Total pledges receivable, net	656,195	50,000	237,371	901,580	1,845,146	3,052,031
Less current portion	(625,098)	(50,000)	(189,371)	(325,500)	(1,189,969)	(2,822,368)
Noncurrent Portion of Pledges Receivable, Net	\$ 31,097	\$ -	\$ 48,000	\$ 576,080	\$ 655,177	\$ 229,663

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

Note 2 - Continued

Foundation pledges and pledges for capital assets included in the above table are considered long term on the consolidated balance sheet.

In 2019, the Organization started the Act I Campaign with the goal of raising over \$20 million in contributions to support Artistic Vitality, Sustainability, and Generous & Inclusive Practices over three years. The Organization has completed the campaign and raised approximately \$20.7 million. During the years ended June 30, 2025 and 2024, the Organization raised \$335,101 and \$4,073,025, respectively.

In 2024, the Organization started the Artistic Investment Fund (AIF) Campaign to support Artistic Director's bold vision for the Theatre. During the year ended June 30, 2025 and 2024, the Organization raised \$3,117,163 and \$26,000, respectively for the AIF Campaign.

Note 3 - Investments and Fair Value Measurements

Investments consisted of the following at June 30:

	<u>2025</u>	<u>2024</u>
Cash equivalents	\$ 106	\$ 6,634
Mutual funds-		
Cash		76,618
Equities	5,595,816	4,974,259
Fixed income	982,355	1,642,287
Alternatives	<u>545,355</u>	<u>501,809</u>
Total mutual funds	7,123,526	7,194,973
Exchange traded funds-		
Equities	4,548,486	4,382,888
Fixed income	<u>2,558,217</u>	<u>1,145,412</u>
Total exchange traded funds	<u>7,106,703</u>	<u>5,528,300</u>
Real Estate Income Trust (REIT)	<u>860,507</u>	<u>816,319</u>
Total Investments	<u><u>\$ 15,090,842</u></u>	<u><u>\$ 13,546,226</u></u>

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

Note 3 - Continued

Investment income was as follows for the years ended June 30:

	<u>2025</u>	<u>2024</u>
Interest and dividends, net of investment fees of \$65,628 (2024 - \$61,078)	\$ 244,878	\$ 243,968
Realized gain	786,366	217,710
Unrealized gain	<u>512,335</u>	<u>1,314,697</u>
Total Endowment Investment Return	<u>\$ 1,543,579</u>	<u>\$ 1,776,375</u>

Fair Value Measurements - U.S. GAAP provides a framework for measuring fair value. To increase consistency and comparability in fair value measurements, the framework requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the primary or most advantageous market for the asset or liability in an orderly transaction between market participants.

The framework uses a three-level valuation hierarchy based on observable and nonobservable inputs. Observable inputs consist of data obtained from independent sources. Nonobservable inputs reflect industry assumptions. These two types of inputs are used to create the fair value hierarchy, giving preference to observable inputs.

Assets classified as Level 1 have fair values based on unadjusted quoted market prices for identical instruments in active markets. Assets and liabilities classified as Level 2 have fair values based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in inactive markets, and model-derived valuations whose inputs are observable. Assets and liabilities classified as Level 3 have fair values based on value drivers that are unobservable.

The following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at June 30, 2025 and 2024.

Cash Equivalents - Consist primarily of money market funds and are valued at the closing price reported on the active markets in which the securities are traded at fiscal year end.

Mutual Funds - Valued at quoted market prices in active markets, which represent the net asset value (NAV) of shares held by the Organization at fiscal year end.

Exchange Traded Funds - Valued at quoted market prices in active markets in which the securities are traded at fiscal year end.

The valuation methodologies used by the Organization may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Organization's management believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

Note 3 - Continued

Total investments and fair values of assets measured on a recurring basis were as follows:

	Fair Value Measurements as of June 30, 2025			
	Level 1	Level 2	Level 3	Total
Cash equivalents	\$ 106	\$ -	\$ -	\$ 106
Mutual funds-				
Equities	5,595,816			5,595,816
Fixed income	982,355			982,355
Alternatives	545,355			545,355
Exchange traded funds-				
Equities	4,548,486			4,548,486
Fixed income	2,558,217			2,558,217
Total Investments in the Fair Value Hierarchy	\$ 14,230,335	\$ -	\$ -	14,230,335
Investments measured at NAV ^(a)				860,507
Total Investments				\$ 15,090,842

	Fair Value Measurements as of June 30, 2024			
	Level 1	Level 2	Level 3	Total
Cash equivalents	\$ 6,634	\$ -	\$ -	\$ 6,634
Mutual funds-				
Cash	76,618			76,618
Equities	4,974,259			4,974,259
Fixed income	1,642,287			1,642,287
Alternatives	501,809			501,809
Exchange traded funds-				
Equities	4,382,888			4,382,888
Fixed income	1,145,412			1,145,412
Total investments in the fair value hierarchy	12,729,907			12,729,907
Investments measured at NAV ^(a)				816,319
Total Investments	\$ 12,729,907	\$ -	\$ -	\$ 13,546,226

- (a) In accordance with U.S. GAAP, certain investments that were measured at fair value using the net asset value (NAV) per share (or its equivalent) practical expedient, which is industry standard, have not been classified in the fair value hierarchy. The fair value amounts presented in these tables are intended to permit reconciliation of the fair value hierarchy to the investment line item presented in the consolidated balance sheet.

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

Note 3 - Continued

The table below summarizes the significant terms of the agreements with certain investment companies. The Organization has no unfunded commitments on its investments.

Asset Class	NAV June 30, 2025	NAV June 30, 2024	Redemption Frequency	Redemption Notice Period	Redemption Restrictions
Real estate	\$ 528,031	\$ 516,465	Monthly	Monthly	Limited to 2% of total fund's NAV per month and 5% per calendar quarter
Infrastructure	332,476	299,854	Quarterly	Quarterly	Limited to 5% of funds total NAV
	<u>\$ 860,507</u>	<u>\$ 816,319</u>			

Note 4 - Property and Equipment

Property and equipment at June 30 was as follows:

	2025	2024
Building and leasehold improvements	\$ 14,224,412	\$ 13,285,926
Equipment and furniture	3,803,406	3,568,764
	18,027,818	16,854,690
Accumulated depreciation	(11,464,649)	(10,674,895)
Total Property and Equipment	\$ 6,563,169	\$ 6,179,795

Note 5 - Net Assets Without Donor Restrictions

As of June 30, 2025 and 2024, net assets without donor restrictions were as follows:

	2025	2024
Undesignated net assets	\$ 3,446,556	\$ 2,553,645
Board designated net assets-		
Operating reserves	1,984,768	1,400,209
Capital reserves	12,851	12,851
Quasi-endowment	1,102,100	
Total board designated net assets	3,099,719	1,413,060
Total Net Assets Without Donor Restrictions	\$ 6,546,275	\$ 3,966,705

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

Note 6 - Net Assets With Donor Restrictions

Net assets with donor restrictions were restricted for the following purposes or periods at June 30:

	2025	2024
Subject to the Passage of Time or Expenditure for Specified Purpose:		
Campaign	\$ -	\$ 4,194,963
General support for future periods	647,388	417,605
Total Subject to the Passage of Time or Expenditure for Specified Purpose	647,388	4,612,568
Endowment Funds:		
Original gifts and required retained earnings (corpus)-		
Theater operations funds:		
General	5,213,595	5,078,615
Bill and Melinda Gates Foundation	2,500,000	2,500,000
Bagley and Virginia Wright and The Wright Family Fund	1,000,000	1,000,000
Winky and Peter Hussey Fund	624,144	624,144
Fox Family Endowment in Memory of Rita D. Fox	250,000	250,000
Mary F. Stowe Fund	135,037	131,607
Jim and Camille Uhlir Fund	50,250	50,250
Education-		
Peter Donnelly Fund	240,953	240,953
William Randolph Hearst Endowment for Education	200,000	200,000
The Allen Foundation for the Arts	500,000	500,000
Artistic development-		
General	25,000	25,000
Daniel Sullivan Artistic Development Fund	1,240,746	1,240,746
Kreielsheimer Signature Works Fund	1,993,063	1,941,086
The Stuart Smailes Signature Works Fund	109,850	109,850
Henry and Nancy Ketcham Foundation	50,000	50,000
George and Carlyn Steiner Guest Artist Fund	155,761	151,653
Actors Fund	50,000	50,000
New Works-		
General	25,000	25,000
Mary Davis Clapp Fund for New Works	2,504,944	2,504,944
Laura Lundgren Fund for New Work	101,591	101,591
Herman and Faye Sarkowsky Commissioning Fund	100,000	100,000
Jerry Manning Fund for New Work	50,000	50,000
Playwright Commission Fund	30,000	30,000
	17,149,934	16,955,439
Accumulated deficit	(2,201,778)	(2,802,366)
Total Endowment Funds	14,948,156	14,153,073
Total Net Assets With Donor Restrictions	\$ 15,595,544	\$ 18,765,641

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

Note 7 - Endowment Funds

The Organization's endowment consists of 23 individual funds as of June 30, 2025, and 2024 established within a framework of four restricted purposes: theater operations, education, artistic development and new works. The donor contributions are maintained in perpetuity, the income of which is expendable for the donors' intended purpose in proportion to each fund's percentage of the total endowment fund corpus. Annual distributions are in accordance with the Organization's distribution policy.

The Organization is subject to the Washington State Prudent Management of Institutional Funds Act (PMIFA). The Board of Trustees of the Organization has interpreted PMIFA as not requiring the maintenance of purchasing power of the original gift amount contributed to an endowment fund, unless a donor stipulates the contrary. As a result of this interpretation, when reviewing its donor-restricted endowment funds, the Organization considers the value of a fund to be deficient if the fair value of the fund is less than the sum of (a) the original value of initial and subsequent gift amounts donated to the fund and (b) any accumulations to the fund that are required to be maintained in perpetuity in accordance with the direction of the applicable donor gift instrument. The Organization has interpreted PMIFA to permit spending from deficient funds in accordance with the prudent measures required under the law. Additionally, in accordance with PMIFA, the Organization considers the following factors, included in its distribution policy, in making a determination to appropriate or accumulate donor-restricted endowment funds:

1. The duration and preservation of the endowment fund;
2. The purposes of the organization and the endowment fund;
3. General economic conditions;
4. The possible effect of inflation and deflation;
5. The expected total return from income and the appreciation of investments;
6. Other resources of the organization; and
7. The investment policies of the Organization.

Utilizing the framework of total investment return, the investment objective and guidelines of the endowment portfolio emphasizes long-term growth of capital while providing annual distributions from the endowment fund to support Theater operations over the long term, while limiting volatility. It is acknowledged that volatility is inherent in any long-term growth strategy. Short-term volatility will be tolerated to the extent it is consistent with the volatility of a comparable market index.

The Organization has a 4% distribution policy, based on a three-year rolling average of market value of endowment investments at December 31 each year. This distribution is approved by the Foundation Board of Directors for use in the next fiscal year of the Theater's operations. From time to time, the Foundation may make additional distributions to the Theater.

In addition to a review of monthly investment performance reports, the Organization meets with the endowment's investment manager quarterly to ensure that the investment guidelines and objectives are being followed.

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

Note 7 - Continued

Changes to endowment net assets for the years ended June 30, 2025 and 2024 were as follows:

	Quasi Endowment	With Donor Restrictions Endowment Corpus	Accumulated Deficit	Total
Endowment net assets, June 30, 2023	\$ -	\$ 16,233,362	\$ (3,648,120)	\$ 12,585,242
Endowment investment return*		97,933	1,678,442	1,776,375
Endowment contributions		624,144		624,144
Endowment related expenses			(55,665)	(55,665)
Foundation transfer of support			(777,023)	(777,023)
Endowment Net Assets, June 30, 2024		16,955,439	(2,802,366)	14,153,073
Endowment investment return*		59,514	1,484,065	1,543,579
Endowment contributions		134,981		134,981
Board designation	1,102,100			1,102,100
Endowment related expenses			(107,030)	(107,030)
Foundation transfer of support			(776,447)	(776,447)
Endowment Net Assets, June 30, 2025	\$ 1,102,100	\$ 17,149,934	\$ (2,201,778)	\$ 16,050,256

* Three individual endowment funds require a portion of the annual investment income to be added to the corpus of the fund.

From time to time, the fair value of assets associated with donor restricted endowment funds may fall below the level that donors require the Organization to retain as a fund of perpetual duration. At June 30, 2025 and 2024, deficiencies of this nature exist in 18 and 20 individual funds, respectively. These deficiencies of \$2,289,730 and \$2,846,182, respectively include original gift values of \$16,083,402 and \$16,048,035 respectively, and current market value of \$13,793,672 and \$13,201,853, at June 30, 2025 and 2024, respectively. These deficiencies resulted from appropriations for programs that were deemed prudent by the Foundation's Board of Directors that exceeded net investment returns.

Note 8 - Lease Commitments

The Organization has a lease agreement with the City of Seattle for the Bagley Wright Theater. The rental cost for the theater was \$8,546 per month, adjusted for the change in All-Urban Consumer Price Index (CPI) on January 1st of each year through September 30, 2014. On September 30, 2014, rent was reduced to \$1 per month until the expiration of the lease in June 2026, contingent on the Organization expending \$1,000,000 in 2010 dollars (plus an adjustment for the change in CPI) on capital renovations and improvement to the Bagley Wright Theater premises by September 30, 2018 along with other required milestones related to those capital projects. On September 27, 2019, the Organization received a letter from the City of Seattle confirming that the required capital renovation expenditures were met by the September 30, 2018 deadline.

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

Note 8 - Continued

The lease also requires annual payments averaging approximately \$150,000 through the remainder of the lease term to a "maintenance reserve fund" to support the theatrical and building systems in the Bagley Wright Theater. During the year ended June 30, 2024, the City of Seattle approved a 4th amendment to the lease allowing The Organization to draw down the current balance to reimburse the Organization for its expenditures for Phases I and II of the lobby renovation project. Additionally, the amendment allows the Organization to spend the future maintenance reserve fund payments for the remaining term of the lease directly on the final phase of the lobby renovation. In accordance with the amendment, the Organization drew down the balance to zero during the year ended June 30, 2024.

The Organization has a lease agreement with the City of Seattle for the land on which the Leo Kreielsheimer Theater (Leo K.) was constructed. The lease requires an annual payment of \$5,515 and expires in the year 2026. Upon expiration of the lease, ownership of the Leo K. Theater will transfer to the City of Seattle.

The Organization leases storage space and apartments under operating leases on a month-to-month basis, and leases rehearsal space as needed on a week-to-week basis.

The Organization leases theater equipment under noncancelable financing leases that expired during the year ended June 30, 2025.

Note 9 - Employee Retirement Plan

The Organization has a Tax Deferred Annuity Plan (the Plan) allowing all eligible employees to defer a portion of their earnings on a pre-tax basis. There were no employer contributions made to the Plan during the years ended June 30, 2025 and 2024. The Plan qualifies as a tax deferred plan under section 401(k) of the Internal Revenue Code. The Organization made retirement related payments on behalf of its employees participating in collective bargaining units totaling \$339,820 and \$245,004 during the years ended June 30, 2025 and 2024, respectively.

Note 10 - Collective Bargaining Agreements

The Organization has several multi-year collective bargaining agreements with specific union locals that cover the work of their stage crews, costume shop and wardrobe, scenic painters, and musicians. They also participate in three national labor agreements covering the work of their actors and stage managers, directors, and designers. All of these agreements include specific stipulations covering working conditions, wage rates, and benefit percentages, including health and welfare and pension. These agreements have various ending dates through 2025. These relationships are core to the Organization's ability to produce theatre, and management works closely with union representatives throughout the contract periods to facilitate timely renewal of all contracts.

Note 11 - Line of Credit

The Organization has a line of credit with a bank with an available borrowing limit of \$4.5 million that expires on March 31, 2026. At June 30, 2025, the line carried interest at the Daily Simple SOFR rate plus 1.68% (a total borrowing rate of 5.82% and 6.99% at June 30, 2025 and 2024, respectively). The outstanding balance at June 30, 2025 and 2024 was \$1,145,000 and \$65,000, respectively. The line is secured by the investments held by the Foundation (at another bank).

SEATTLE REPERTORY THEATER

Notes to Consolidated Financial Statements For the Year Ended June 30, 2025 (With Comparative Totals for 2024)

Note 12 - Liquidity and Availability of Financial Assets

The Organization's working capital and cash flows have seasonal variations during the year attributable to the annual cash receipts for prepaid subscription revenue in the fourth quarter of the fiscal year in advance of the next year and a concentration of contributions received near calendar year end and fiscal year end. Monthly cash outflows vary each year based on the specific requirements of the productions programmed that season. To manage liquidity the Organization maintains a line of credit of \$4.5 million with a bank that is drawn upon as needed during the year to manage cash flow. See Note 11 for further description of this line.

The following reflects the Organization's financial assets as of the consolidated balance sheet date, reduced by amounts not available for general use within one year of the consolidated balance sheet date because of contractual or donor-imposed restrictions or internal designations. Amounts available include the Foundation Board-approved appropriation from the endowment fund for the following year as well as donor-restricted amounts that are available for expenditure in the following year. Amounts not available include amounts set aside for operating and other reserves that could be drawn upon if the Theater or Foundation Board approves that action.

	2025	2024
Cash, cash reserves, and restricted cash	\$ 2,150,734	\$ 2,089,434
Accounts receivable, net, due to be collected in less than one year	101,984	107,004
Pledges receivable	1,845,146	3,052,031
Investments	15,090,842	13,546,226
Total financial assets	19,188,706	18,794,695
Board designations-		
Quasi-endowment	(1,102,100)	
Operating reserves and other	(1,997,619)	(1,413,060)
Contractual or donor-imposed restrictions-		
Cash restricted by lessor and others to specific uses	(21,347)	(16,838)
Net assets with donor restrictions	(15,595,544)	(18,765,641)
Donor-imposed restrictions available for use within one year-		
Board approved endowment appropriation for the following year	833,718	776,447
Donor restricted net assets available for use within one year	569,000	4,584,597
Financial Assets Available to Meet Cash Needs for General Expenditures Within One Year	\$ 1,874,814	\$ 3,960,200

SUPPLEMENTARY INFORMATION

SEATTLE REPERTORY THEATER

Consolidating Schedule - Balance Sheet June 30, 2025

	Theater	Foundation	Total
Assets			
Current Assets:			
Cash	\$ 131,768	\$ -	\$ 131,768
Cash reserves (Note 1)	1,997,619		1,997,619
Restricted cash (Note 1 and 8)	21,347		21,347
Accounts receivable, net	101,984		101,984
Pledges receivable, net (Note 2)	1,139,869	100	1,139,969
Interfund receivable (payable)	(959,314)	959,314	
Prepaid expenses and inventory	461,708		461,708
Total Current Assets	2,894,981	959,414	3,854,395
Investments, long-term (Note 3)		15,090,842	15,090,842
Pledges receivable for capital purposes (Note 2)	50,000		50,000
Pledges receivable, long-term, net (Note 2)	655,177		655,177
Property and equipment, net of accumulated depreciation (Note 4)	6,563,169		6,563,169
Financing lease, right-of-use asset (Note 8)			
Total Assets	\$ 10,163,327	\$ 16,050,256	\$ 26,213,583
Liabilities and Net Assets			
Current Liabilities:			
Deferred ticket revenue	\$ 1,816,543	\$ -	\$ 1,816,543
Accounts payable and accrued liabilities	1,110,221		1,110,221
Line of credit (Note 11)	1,145,000		1,145,000
Total Liabilities	4,071,764		4,071,764
Net Assets:			
Without donor restrictions (Note 5)	5,444,175	1,102,100	6,546,275
With donor restrictions (Note 6)	647,388	14,948,156	15,595,544
Total Net Assets	6,091,563	16,050,256	22,141,819
Total Liabilities and Net Assets	\$ 10,163,327	\$ 16,050,256	\$ 26,213,583

See independent auditor's report.

SEATTLE REPERTORY THEATER

Consolidating Schedule - Statement of Activities For the Year Ended June 30, 2025

	Theater	Foundation	Total
Revenue			
Box Office Income:			
Subscription revenue	\$ 2,055,721	\$ -	\$ 2,055,721
Single ticket revenue	2,191,219		2,191,219
Service fees	421,623		421,623
Total Box Office Income	4,668,563		4,668,563
Other Earned Income:			
Royalty income	161,894		161,894
Production fees	80,681		80,681
Other revenue, net of related expenses	302,970		302,970
Total Other Earned Income	545,545		545,545
Total Earned Income	5,214,108		5,214,108
Contributions:			
Individual gifts	5,151,713		5,151,713
Corporate	168,500		168,500
Foundations	1,324,211		1,324,211
Government	107,937		107,937
Advocacy	536,730		536,730
In-kind gifts	42,738		42,738
Fundraising events, net of related expenses	852,630		852,630
Contributions released from restrictions (Act I campaign, Note 2)	2,335,102		2,335,102
Endowment appropriation (Note 7)	776,447		776,447
Total Contributions	11,296,008		11,296,008
Total Revenue	16,510,116		16,510,116
Expenses:			
Artistic	2,325,325		2,325,325
Production	6,438,828		6,438,828
Marketing and communications	3,368,890		3,368,890
Development	1,146,325	570	1,146,895
Administration	1,816,868	106,460	1,923,328
Total Expenses	15,096,236	107,030	15,203,266
Change in Net Assets Before			
Depreciation and Nonoperating Activity	1,413,880	(107,030)	1,306,850
Depreciation and amortization	799,489		799,489
Nonoperating Activity:			
Contributions to the Act I campaign (Note 2)	335,101		335,101
Endowment investment return		1,543,579	1,543,579
Contributions to endowment		134,981	134,981
Quasi-endowment transfer	(1,102,100)	1,102,100	
Contributions released from restrictions, (Act I campaign, Note 2)	(2,335,102)		(2,335,102)
Endowment appropriation (Note 7)		(776,447)	(776,447)
Total Nonoperating Activity	(3,102,101)	2,004,213	(1,097,888)
Change in Net Assets	(2,487,710)	1,897,183	(590,527)
Net Assets:			
Beginning of year	8,579,273	14,153,073	22,732,346
End of Year	\$ 6,091,563	\$ 16,050,256	\$ 22,141,819

See independent auditor's report.

SEATTLE REPERTORY THEATER

Consolidating Schedule - Statement of Cash Flows For the Year Ended June 30, 2025

	Theater	Foundation	Total
Operating Activities:			
Change in net assets	\$ (2,487,710)	\$ 1,897,183	\$ (590,527)
Adjustments to reconcile change in net assets to net cash (used in) provided by operating activities-			
Depreciation and amortization	799,489		799,489
Net gain on investments		(1,298,701)	(1,298,701)
Contributions and investment return restricted for endowment		(194,495)	(194,495)
Contributions restricted for capital purposes	(126,377)		(126,377)
Cash (used) provided by changes in operating assets and liabilities:			
Accounts receivable	5,020		5,020
Pledges receivable	1,206,885		1,206,885
Pledges receivable for capital purposes	(127,488)		(127,488)
Interfund receivable/payable	352,567	(352,567)	
Prepaid expenses and inventory	(48,923)		(48,923)
Deferred ticket revenue	117,819		117,819
Accounts payable and accrued liabilities	242,539		242,539
Net Cash (Used in) Provided by Operating Activities	(66,179)	51,420	(14,759)
Investing Activities:			
Purchase of investments		(2,731,530)	(2,731,530)
Proceeds from sale of investments		2,485,615	2,485,615
Purchase of property and equipment	(1,177,305)		(1,177,305)
Net Cash Used in Investing Activities	(1,177,305)	(245,915)	(1,423,220)
Financing Activities:			
Collections on contributions and investment return restricted for endowment corpus		194,495	194,495
Collections on contributions for capital purposes	253,865		253,865
Payments on line of credit	(5,952,000)		(5,952,000)
Proceeds from line of credit	7,032,000		7,032,000
Principal payments on financing leases	(29,081)		(29,081)
Net Cash Provided by Financing Activities	1,304,784	194,495	1,499,279
Net Change in Cash	61,300		61,300
Cash, cash reserves, and restricted cash, beginning of year	2,089,434		2,089,434
Cash, Cash Reserves, and Restricted Cash, End of Year	\$ 2,150,734	\$ -	\$ 2,150,734
Reconciliation to Consolidating Schedule - Balance Sheet:			
Cash	\$ 131,768	\$ -	\$ 131,768
Cash reserves	1,997,619		1,997,619
Restricted cash	21,347		21,347
Cash, Cash Reserves and Restricted Cash	\$ 2,150,734	\$ -	\$ 2,150,734
Supplementary Disclosure:			
Cash paid for interest	\$ 15,058	\$ -	\$ 15,058
Acquisition of long-term assets at the conclusion of financing leases	\$ 87,364	\$ -	\$ 87,364

See independent auditor's report.